Current Trials

Psoriasis
Sponsor: AbbVie
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis
18-99 Years
Phase: Phase 3
Start Date: February 2017
End Date: November 2021

Psoriasis
Sponsor: Janssen Research & Development, LLC
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
18 Years and Older
Phase: Phase 3
Start Date: February 2017
End Date: July 2018

Actinic Keratosis
Sponsor: DUSA Pharmaceuticals, Inc.
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
18 Years and Older
Phase: Phase 3
Start Date: March 2017
End Date: January 2018

Psoriasis
Sponsor: Janssen Research & Development, LLC
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
18 Years and Older
Phase: Phase 3
Start Date: April 2017
End Date: November 2018